清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Milestone Analyses of Immune Checkpoint Inhibitors, Targeted Therapy, and Conventional Therapy in Metastatic Non–Small Cell Lung Cancer Trials

医学 重要事件 危险系数 内科学 肺癌 肿瘤科 临床试验 人口 临床终点 随机对照试验 癌症 置信区间 历史 环境卫生 考古
作者
Gideon M. Blumenthal,Qian Zhang,Hui Zhang,Dickran Kazandjian,Sean Khozin,Shenghui Tang,Kirsten B. Goldberg,Rajeshwari Sridhara,Patricia Keegan,Richard Pazdur
出处
期刊:JAMA Oncology [American Medical Association]
卷期号:3 (8): e171029-e171029 被引量:76
标识
DOI:10.1001/jamaoncol.2017.1029
摘要

Novel intermediate end points may be useful to detect signals of early activity and prioritize new therapies to treat patients with advanced malignant neoplasms, including metastatic non-small cell lung cancer (mNSCLC).To explore milestone rate, a proposed intermediate end point for immunotherapy trials.Trials submitted to the US Food and Drug Administration with more than 150 patients and in which the intention-to-treat population was assessed were identified.An initial meta-analysis identified 14 randomized clinical trials for treatment of mNSCLC with active controls submitted to the US Food and Drug Administration from January 1, 2003, through December 31, 2013. An additional 11 randomized clinical trials submitted from January 1, 2014, through December 31, 2016 were included.Two investigators abstracted data and pooled data to compare trial-level milestone ratios with conventional end points.Trial-level milestone ratios for milestone rates were calculated for overall response rate (ORR) within 6 months, 9-month progression-free survival (PFS), 9-month overall survival (OS), and 12-month OS. A weighted linear regression model evaluated associations between milestone ratios and hazard ratios (HRs). Experimental and control arms of trials testing immunotherapy, targeted therapy, and other trials were pooled to compare Kaplan-Meier survival estimates in the 3 therapeutic classes.A total of 20 013 unique patients (65.4% male and 34.6% female; mean age, 60 [range, 18-92] years) with advanced lung cancer were identified in 25 unique trials. A moderate association was observed between 12-month OS milestone ratio and OS HR (R2 = 0.80; 95% CI, 0.63-0.91) and 9-month OS milestone ratio and OS HR (R2 = 0.67; 95% CI, 0.49-0.82). No associations were observed between 9-month PFS milestone ratio and OS HR (R2 = 0.19; 95% CI, 0.03-0.49) or 6-month ORR and OS HR (R2 = 0.05; 95% CI, 0.0001-0.31). The aggregated Kaplan-Meier analysis of immunotherapy trials vs chemotherapy revealed an OS HR of 0.69 (95% CI, 0.63-0.75) and PFS HR of 0.82 (95% CI, 0.76-0.89). Targeted therapy trials vs chemotherapy had an OS HR of 0.98 (95% CI, 0.80-1.19) and PFS HR of 0.48 (95% CI, 0.42-0.56).This analysis of milestone rates suggests a moderate association between OS milestones at 12 or 9 months and OS HR but not 9-month PFS or 6-month ORR milestones and OS HR. Although OS at 12 months had the strongest association with OS HR, it may not be the optimal time for future trials, which will increasingly have immunotherapy as the control, deploy new biomarker-enrichment strategies, and likely enroll patients with longer survival. Milestone rates may be useful as a complementary tool to summarize or interpret trial results or as a secondary end point in exploratory studies.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
爱静静应助科研通管家采纳,获得10
11秒前
爱静静应助科研通管家采纳,获得10
11秒前
爱静静应助科研通管家采纳,获得10
11秒前
Emperor完成签到 ,获得积分0
14秒前
52秒前
忍冬半夏发布了新的文献求助10
57秒前
忍冬半夏完成签到,获得积分10
1分钟前
ww完成签到,获得积分10
1分钟前
LULU完成签到,获得积分10
1分钟前
1分钟前
星辰大海应助科研通管家采纳,获得10
2分钟前
爱静静应助科研通管家采纳,获得10
2分钟前
2分钟前
YOKO发布了新的文献求助10
2分钟前
科研通AI2S应助he~tui~~采纳,获得10
2分钟前
情怀应助YOKO采纳,获得10
3分钟前
方白秋完成签到,获得积分10
3分钟前
1437594843完成签到 ,获得积分10
3分钟前
爱静静应助科研通管家采纳,获得10
4分钟前
爱静静应助科研通管家采纳,获得10
4分钟前
爱静静应助科研通管家采纳,获得10
4分钟前
合不着完成签到 ,获得积分10
4分钟前
5分钟前
充电宝应助如意的思真采纳,获得10
6分钟前
爱静静应助科研通管家采纳,获得10
6分钟前
敏感的百招完成签到,获得积分10
6分钟前
土豪的灵竹完成签到 ,获得积分10
7分钟前
Ze萍完成签到 ,获得积分10
8分钟前
cc完成签到,获得积分10
8分钟前
爱静静应助科研通管家采纳,获得10
8分钟前
背书强完成签到 ,获得积分10
8分钟前
8分钟前
gwbk完成签到,获得积分10
8分钟前
灵巧寄风完成签到,获得积分10
9分钟前
可爱的函函应助清雨采纳,获得10
10分钟前
爱静静应助科研通管家采纳,获得10
10分钟前
10分钟前
清雨发布了新的文献求助10
10分钟前
清雨完成签到,获得积分10
10分钟前
liu95完成签到 ,获得积分10
10分钟前
高分求助中
Evolution 10000
Distribution Dependent Stochastic Differential Equations 500
A new species of Coccus (Homoptera: Coccoidea) from Malawi 500
A new species of Velataspis (Hemiptera Coccoidea Diaspididae) from tea in Assam 500
PraxisRatgeber: Mantiden: Faszinierende Lauerjäger 500
Die Gottesanbeterin: Mantis religiosa: 656 400
Mantiden: Faszinierende Lauerjäger Faszinierende Lauerjäger 400
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3158649
求助须知:如何正确求助?哪些是违规求助? 2809798
关于积分的说明 7883715
捐赠科研通 2468521
什么是DOI,文献DOI怎么找? 1314297
科研通“疑难数据库(出版商)”最低求助积分说明 630575
版权声明 601983